Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Gains from Sales and Divestitures (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Gains from Sales and Divestitures for 11 consecutive years, with $230299.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 90.55% year-over-year to $230299.0, compared with a TTM value of $230299.0 through Dec 2025, down 90.55%, and an annual FY2025 reading of $230299.0, down 90.55% over the prior year.
  • Gains from Sales and Divestitures was $230299.0 for Q4 2025 at Karyopharm Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $957.7 million in Q4 2022 and bottomed at $230299.0 in Q4 2025.
  • Average Gains from Sales and Divestitures over 5 years is $192.4 million, with a median of $1.1 million recorded in 2023.
  • The sharpest move saw Gains from Sales and Divestitures surged 199323.22% in 2022, then tumbled 99.89% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $480249.0 in 2021, then soared by 199323.22% to $957.7 million in 2022, then crashed by 99.89% to $1.1 million in 2023, then soared by 132.04% to $2.4 million in 2024, then plummeted by 90.55% to $230299.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for KPTI at $230299.0 in Q4 2025, $2.4 million in Q4 2024, and $1.1 million in Q4 2023.